Drugs / rAAVrh74.MHCK7.DYSF.DV
rAAVrh74.MHCK7.DYSF.DV
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02710500 | Mar 2016 → Jul 2019 | neuromuscular disease caused by qualitative or quantitative defects of dysferlin | Sarepta Therapeutics, Inc. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | rAAVrh74.MHCK7.DYSF.DV | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02710500 ↗ |
| Modality | Gene therapy (AAV / viral vector) | “Recombinant adeno-associated virus” NCT02710500 ↗ |
| Route | Intramuscular | “direct intramuscular injection” NCT02710500 ↗ |
| Target | DYSF | “Biological/Vaccine: rAAVrh74.MHCK7.DYSF.DV Recombinant adeno-associated virus carrying a dysferlin transgene under control of a muscle specific MHCK7 promoter.” NCT02710500 ↗ |